NCT06253000Recruiting
Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium
Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times. The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA). The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- First submitted
- 2 Feb 2024
- Start date
- 10 Jun 2023
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT06253000
What you commit to
- Study type: Interventional
- Planned participants: 158
- From 10 Jun 2023 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous "open" cardiac surgery;
Other illness
- The presence of another cardiac pathology requiring surgical treatment;
- Congenital heart defects;
- Bone marrow diseases;
- Drug-resistant hypertension (despite hypotensive therapy);
Lab values
- The left ventricular ejection fraction is less than 40%;
- Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min);
Age
- Age under 18 and over 80 years old;
Other
- Pathology of the blood coagulation system;
- Organically altered mitral valve;
- There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;
- The patient's participation in another clinical trial.
Who the study is looking for
- Age over 18 years old;
- Atrial fibrillation resistant to antiarrhythmic therapy;
- Persistent and long-persisting form of atrial fibrillation;
- The patient's consent to participate in the study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bakulev National Medical Research Center for Cardiovascular Surgery Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.